Bako, H
Within the class S4 of hormone and metabolic modulators of the WADA Prohibited List, 39% of the adverse analytical findings (AAF) reported in 2020 resulted from SERMs (tamoxifen and clomiphene) and another 29% from AIs (letrozole, anastrozole, exemestane, and adrostatrienedione) (World Anti-Doping Agency, 2022)
Conditions such as kidney failure, chronic kidney disease, and nephrotic syndrome have been associated with fluid retention in the face and lower limbs
For patients with pernicious anemia, severe malabsorption, or acute neurological symptoms, injections remain the appropriate clinical choice
PMC 4425171
Data from participants who received the same injection dose (the saline injection group and the 1 10 7 DPSCs per tooth injection group) across both trials were pooled for analysis, and baseline characteristics for these combined participants were verified (Supplementary Table 13)